She then became a clinical rotational pharmacist at a hospital in Hertfordshire where she obtained her Post Graduate Certificate. Poor metabolizers, who lack CYP2C19, may be particularly predisposed to drug interactions. Until more is known, patients should be advised to be alert for an increase in citalopram adverse effects (such as dry mouth, increased sweating, or insomnia) when taking omeprazole. The clinical implications of the present study merit further investigations.This study was supported by a grant from the Chi‐Mei Hospital(107‐CM‐FJU‐06).The authors thank the enrollees of the National Health Insurance Research Database for important contributions. Stephanie joined the Pharmaceutical Press in January 2014 as a Clinical Writer for the Editorial Team.Sonia Khan, MPharm, PGCertPharmPrac, studied pharmacy at the University of East Anglia, graduating in 2007. Because the exposure in the observational cohort is time‐dependent and non‐proportional hazards of SCA exist between study cohorts, as indicated by the Schoenfeld global test (Data for 35 377 patients who were prescribed for citalopram and/or omeprazole between 2000 and 2005 were retrieved from NHIRD. Number of DDDs was calculated as the total amount of days per prescription divided by amount of drug in a DDD. After ensuring that he is aware of potential interaction effects and what to do if he experiences any, you sell it to him. organization.Arteriosclerosis, Thrombosis, and Vascular Biology (ATVB)The spectrum of epidemiology underlying sudden cardiac deathDepression is a risk factor for coronary artery disease in men: the Precursors StudyNational patterns in antidepressant medication treatmentCyclic antidepressants and the risk ofsudden cardiac deathExcess risk of myocardial infarction in patients treated with antidepressant medications: association with use of tricyclic agentsCardiovascular effects of antidepressant drugs: updatedCitalopram in the treatment of depression and other potential uses inpsychiatryMechanism of action of serotonin selective reuptake inhibitors: serotonin receptors and pathways mediate therapeutic effects and side effectsFDA drug safety communication: Abnormal heart rhythmsassociated with high doses of Celexa (Citalopram Hydrobromide)Influence of CYP2C19pharmacogenetic polymorphism on proton pump inhibitor‐based therapiesPharmacokinetics of citalopram in relation to genetic polymorphism of CYP2C19Impact of the ultrarapid CYP2C19*17 allele on serum concentration of escitalopram in psychiatric patientsNon‐response to citalopram in depressive patients: pharmacokinetic and clinical consequences of a fluvoxamine augmentationIdentification of human liver cytochrome P450 isoforms mediating secondary omeprazole metabolismEffect of omeprazole on the pharmacokinetics of moclobemide according to the genetic polymorphism of CYP2C19Comparison of inhibitory effects of the proton pump‐inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 activitiesEffects of omeprazoleand genetic polymorphism of CYP2C19 on the clopidogrel active metaboliteInhibition of CYP2C19 and CYP3A4 by omeprazole metabolites and their contribution to drug‐drug interactionsA population‐based study of the drug interaction between proton pump inhibitors and clopidogrelAssociation between nucleosid analogues and risk of hepatitis B virus–related hepatocellular carcinoma recurrence following liver resectionValidation of the National Health Insurance Research Database with ischemic stroke cases in TaiwanComparative risk of ventricular arrhythmia and sudden cardiac death across antidepressants in patients with depressive disordersRisk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndromeDepression and risk of sudden cardiac death and coronary heart disease in women: results from the Nurses’ Health StudyAntidepressant use and risk of incident cardiovascular morbidity and mortality among postmenopausal women in the Women's Health Initiative StudyAntidepressant use and risk of out‐of‐hospital cardiac arrest: a nationwide case–time–control studyFamotidine is inferior to pantoprazole in preventing recurrence of aspirin‐related peptic ulcers or erosionsAdverse effects associated with proton pump inhibitorsInfluence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, double‐blind OCLA (Omeprazole Clopidogrel Aspirin) StudyOutcomes with concurrent use of clopidogrel and proton‐pump inhibitors: a cohort studyProton‐pump inhibitors are associated with increased cardiovascular risk independent of clopidogrel use: a nationwide cohort studyProton pump inhibitor usage and the risk of myocardial infarction in the general populationOmeprazole preferentially inhibits themetabolism of (+)‐(S)‐citalopram in healthy volunteersThe proton pump inhibitor, omeprazole, but not lansoprazole or pantoprazole, is a metabolism‐dependent inhibitor of CYP2C19: implications for coadministration with clopidogrelThe effect of cimetidine or omeprazole on the pharmacokinetics of escitalopram in healthy subjectsClinical relevance of the (S)‐citalopram‐omeprazole interaction in geriatric patients In some cases, omeprazole is also utilized as a prophylactic to … PMID: 11396546 [Indexed for MEDLINE] Publication Types: Review; MeSH terms With numerous illustrations and case studies.Explains drug testing regulatory frameworks and all aspects of drug analysis. ... (Prandin ®). For patients on longer-term treatment with omeprazole, consideration should be given to decreasing the dose of the SSRI if citalopram adverse effects become troublesome.Pantoprazole, another proton pump inhibitor available for OTC sale, does not inhibit CYP2C19 to a clinically relevant extent, and would be a more suitable alternative for this patient. Moreover, all data in the NHIRD are anonymous; therefore, relevant clinical variables such as serum laboratory data and pathology results were also unavailable.Strengths of this study include a nationwide cohort study based on Taiwan's NHIRD, which contains data from Taiwan's compulsory and universal healthcare system with high coverage rate.